CN110464709A - 用于治疗中风的神经保护性脂质体组合物和方法 - Google Patents

用于治疗中风的神经保护性脂质体组合物和方法 Download PDF

Info

Publication number
CN110464709A
CN110464709A CN201910643063.1A CN201910643063A CN110464709A CN 110464709 A CN110464709 A CN 110464709A CN 201910643063 A CN201910643063 A CN 201910643063A CN 110464709 A CN110464709 A CN 110464709A
Authority
CN
China
Prior art keywords
elip
liposomes
composition
stroke
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910643063.1A
Other languages
English (en)
Chinese (zh)
Inventor
黄韶玲
M·E·克莱格曼
耿永健
金亨建
D·D·麦克弗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN110464709A publication Critical patent/CN110464709A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910643063.1A 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法 Pending CN110464709A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682130P 2012-08-10 2012-08-10
US61/682,130 2012-08-10
CN201210356929.9A CN103565745A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201210356929.9A Division CN103565745A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Publications (1)

Publication Number Publication Date
CN110464709A true CN110464709A (zh) 2019-11-19

Family

ID=50039028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910643063.1A Pending CN110464709A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法
CN201210356929.9A Pending CN103565745A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210356929.9A Pending CN103565745A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法

Country Status (7)

Country Link
US (4) US10369103B2 (cg-RX-API-DMAC7.html)
EP (2) EP2882422B1 (cg-RX-API-DMAC7.html)
JP (1) JP6297040B2 (cg-RX-API-DMAC7.html)
CN (2) CN110464709A (cg-RX-API-DMAC7.html)
AU (1) AU2013299453B2 (cg-RX-API-DMAC7.html)
CA (2) CA3132444C (cg-RX-API-DMAC7.html)
WO (1) WO2014026117A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
CN110354067A (zh) 2013-03-15 2019-10-22 德克萨斯州大学系统董事会 富含稀有气体的液体及其制备和使用方法
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
US10456483B2 (en) 2014-12-03 2019-10-29 University Of Cincinnati Gas-encapsulated acoustically responsive stabilized microbubbles and methods for treating cardiovascular disease
JP6622822B2 (ja) * 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
CZ307851B6 (cs) 2017-02-14 2019-06-26 Ústav experimentální medicíny AV ČR, v. v. i. Léčebný přípravek k prevenci a léčení zánětlivých a degenerativních onemocnění
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法
JP2022144013A (ja) * 2021-03-18 2022-10-03 橋本電子工業株式会社 抗血栓リポソーム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668315A (zh) * 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
US20080175893A1 (en) * 2006-10-16 2008-07-24 Northwestern University Gas-containing liposomes
US20120087956A1 (en) * 2007-12-22 2012-04-12 Simpkins Cuthbert O Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5858399A (en) 1992-04-09 1999-01-12 Northwestern University Acoustically reflective liposomes and methods to make and use the same
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US6123919A (en) 1994-04-08 2000-09-26 The Trustees Of Princeton University Magnetic resonance imaging using hyperpolarized noble gases
US5545396A (en) 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
ES2167608T3 (es) 1995-10-20 2002-05-16 L Air Liquide S A Directoire E Composicion basada en monoxido de nitrogeno como medicamento.
ATE209902T1 (de) 1996-08-19 2001-12-15 Us Gov Health & Human Serv Neue liposomkomplexe mit erhöhter systemischer verabreichung
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6050444A (en) 1998-07-22 2000-04-18 Sugg; James Wesley Consumable beverage dispenser with one-way valve
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19933704A1 (de) 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
DE10054563A1 (de) 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
WO2002045721A1 (en) 2000-12-04 2002-06-13 Uws Ventures Limited Noble gas complexes
DE60111917T2 (de) 2001-01-31 2006-04-20 Bracco International B.V. Lyophilisierbares Kontrastmittel, gasgefüllte Mikrobläschen enthaltend
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
ATE468861T1 (de) 2001-08-16 2010-06-15 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
US7202089B2 (en) 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
GB0209998D0 (en) 2002-05-01 2002-06-12 Protexeon Ltd Use
DE10328272A1 (de) 2002-06-22 2004-01-15 Messer Griesheim Gmbh Medikament mit Xenon und NO
ES2354607T3 (es) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. Procedimiento y aparato para producir liposomas.
WO2004004782A1 (de) 2002-07-05 2004-01-15 Messer Griesheim Gmbh Xenon enthaltendes adjuvans
GB0218153D0 (en) 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
DE10336768B4 (de) 2002-08-10 2010-09-09 Air Liquide Deutschland Gmbh Medikament zur Verbesserung der Sauerstoffutilation
DE10336778B4 (de) 2002-08-10 2010-09-16 Air Liquide Deutschland Gmbh Stabilisierung eines Patienten mit einem xenonhaltigen Gas
CA2500468A1 (en) 2002-09-28 2004-04-08 Massachussets Institute Of Technology Influenza therapeutic
CA2547531C (en) 2002-11-26 2013-11-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
FR2849779B1 (fr) 2003-01-15 2006-07-14 Air Liquide Sante Sa Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques
US7198179B2 (en) 2003-02-25 2007-04-03 Therox, Inc. System for storing and dispensing a gas-solubilized product
US20060019868A1 (en) 2004-01-30 2006-01-26 Pendharkar Sanyog M Hemostatic compositions and devices
CA2538104C (en) 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
EP1552840A1 (en) 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
EP1714642A1 (en) 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
WO2006126244A1 (ja) * 2005-05-23 2006-11-30 Mebiopharm Co., Ltd. ガス封入リポソームの製造法
JP2009536663A (ja) 2006-05-09 2009-10-15 コルゲート・パーモリブ・カンパニー 口腔ケア措置
US20080187605A1 (en) 2007-02-02 2008-08-07 Olney John W Preventing pathological nerve cell suicide (neuroapoptosis) in immature nervous systems
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
EP1980260A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
CA2685446A1 (en) 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
WO2009075582A2 (en) 2007-12-10 2009-06-18 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
CL2007003772A1 (es) 2007-12-21 2008-04-25 Vulco Sa Procedimiento para la fabricacion de un mandril flexible de poliuretano, que contiene un alma metalica que comprende recubrir con goma un alma metalica, aplicar desmoldante, precalentar el conjunto, curar el poliuretano y enfriar el codo.
PT2349300T (pt) 2008-11-10 2019-12-19 Moleac Pte Ltd Terapia combinada para tratamento de doentes com distúrbios neurológicos e enfarte cerebral
CA2749698C (en) 2009-01-30 2017-08-01 Cuthbert O. Simpkins Resuscitation fluid
FR2944969B1 (fr) 2009-04-29 2011-08-26 Air Liquide Utilisation de n2o gazeux dans le traitement des douleurs chroniques
CA2761455C (en) * 2009-05-13 2018-06-12 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CA2765697C (en) * 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
WO2011091160A1 (en) 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
WO2012020030A1 (en) * 2010-08-09 2012-02-16 Bracco Suisse Sa Targeted gas-filled microvesicles
CN104739765A (zh) 2011-01-14 2015-07-01 卡思伯特·O·辛普金斯 用于处理与缺乏血液供给、休克和神经损伤相关的疾病的方法和组合物
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668315A (zh) * 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
US20080175893A1 (en) * 2006-10-16 2008-07-24 Northwestern University Gas-containing liposomes
US20120087956A1 (en) * 2007-12-22 2012-04-12 Simpkins Cuthbert O Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries

Also Published As

Publication number Publication date
JP2015528441A (ja) 2015-09-28
US11872312B2 (en) 2024-01-16
WO2014026117A2 (en) 2014-02-13
CA3132444C (en) 2023-11-07
AU2013299453B2 (en) 2017-12-14
WO2014026117A3 (en) 2014-10-23
CA3132444A1 (en) 2014-02-13
EP3932394A1 (en) 2022-01-05
EP2882422A2 (en) 2015-06-17
EP2882422A4 (en) 2016-03-16
US20210378959A1 (en) 2021-12-09
CN103565745A (zh) 2014-02-12
EP2882422B1 (en) 2021-04-28
US10369103B2 (en) 2019-08-06
US20150216800A1 (en) 2015-08-06
US10973764B2 (en) 2021-04-13
EP3932394B1 (en) 2024-08-07
US20200101015A1 (en) 2020-04-02
AU2013299453A1 (en) 2015-02-26
CA2881096A1 (en) 2014-02-13
JP6297040B2 (ja) 2018-03-20
CA2881096C (en) 2021-11-16
US20240398708A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
US11872312B2 (en) Neuroprotective liposome compositions and methods for treatment of stroke
US7976743B2 (en) Gas-containing liposomes
JP2007284460A (ja) 弱塩基性薬物を担持するイオン運搬体−中介リポゾーム
PT1443900E (pt) Composições de veículo lipídico com estabilidade melhorada no sangue
WO2010041255A2 (en) Liposomal systems comprising sphingomyelin
RU2756755C2 (ru) Липосомальный препарат для применения для лечения злокачественного новообразования
US11992483B2 (en) Emulsions for local anesthetics
ES2290333T3 (es) Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
US20050008664A1 (en) Compositions and methods related to lipid:emodin formulations
JPWO2013176223A1 (ja) 炎症性疾患治療用医薬組成物
CN117979970A (zh) 布比卡因多囊脂质体制剂及其用途
Uhl et al. Reduction of skin flap necrosis by transdermal application of buflomedil bound to liposomes
EP2753324B1 (en) Lipophilic dopamine derivatives and their use
HK1193995A (en) Neuroprotective liposome compositions and methods for treatment of stroke
HK40017554A (en) Neuroprotective liposome compositions and methods for treatment of stroke
CA3024951C (en) Liposome loading
KR20210131381A (ko) 통증 치료에 사용하기 위한 약학적 조성물
KR20170110320A (ko) 피하주사용 항암제 함유 리포솜 조성물
CN115843246A (zh) 用于治疗血管瘤的方法和组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017554

Country of ref document: HK